Welcome to Vertex Pharmaceuticals.

We believe that, just maybe, we can bring about a profound change in the treatment of serious diseases. This takes cutting-edge science and breakthrough therapies. We’ve built a worldwide community of top researchers and institutions that share our vision for change. With this approach, we think transformative solutions can be achieved even if there is never a “perfect cure.”

About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and bacterial infection. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.

Product Pipeline

The Company is leading the development of the HCV protease inhibitor, telaprevir (VX-950), and in 2007 is conducting a broad Phase 2 clinical program of this drug candidate. Vertex is also focused on the development of VX-702, a p38 MAP kinase inhibitor for the treatment of rheumatoid arthritis, and VX-770, an investigational drug candidate for cystic fibrosis.

Vertex has a worldwide collaboration with Merck & Co. for the development of Aurora kinase inhibitors for the treatment of cancer. Vertex is also collaborating with Avalon Pharmaceuticals on the development of AVN-944 (VX-944), an IMPDH inhibitor targeting hematologic cancers, and with GlaxoSmithKline on the development of certain novel subtype selective sodium channel modulators for the treatment of pain.

Worldwide Locations

Cambridge, MA, USA
San Diego, CA, USA
Abingdon, Oxfordshire, UK